TY - JOUR
T1 - Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection
AU - Côté, Marceline
AU - Misasi, John
AU - Ren, Tao
AU - Bruchez, Anna
AU - Lee, Kyungae
AU - Filone, Claire Marie
AU - Hensley, Lisa
AU - Li, Qi
AU - Ory, Daniel
AU - Chandran, Kartik
AU - Cunningham, James
PY - 2011/9/15
Y1 - 2011/9/15
N2 - Ebola virus (EboV) is a highly pathogenic enveloped virus that causes outbreaks of zoonotic infection in Africa. The clinical symptoms are manifestations of the massive production of pro-inflammatory cytokines in response to infection and in many outbreaks, mortality exceeds 75%. The unpredictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effective vaccine or therapy have created a high level of public concern about EboV. Here we report the identification of a novel benzylpiperazine adamantane diamide-derived compound that inhibits EboV infection. Using mutant cell lines and informative derivatives of the lead compound, we show that the target of the inhibitor is the endosomal membrane protein Niemann-Pick C1 (NPC1). We find that NPC1 is essential for infection, that it binds to the virus glycoprotein (GP), and that antiviral compounds interfere with GP binding to NPC1. Combined with the results of previous studies of GP structure and function, our findings support a model of EboV infection in which cleavage of the GP1 subunit by endosomal cathepsin proteases removes heavily glycosylated domains to expose the amino-terminal domain, which is a ligand for NPC1 and regulates membrane fusion by the GP2 subunit. Thus, NPC1 is essential for EboV entry and a target for antiviral therapy.
AB - Ebola virus (EboV) is a highly pathogenic enveloped virus that causes outbreaks of zoonotic infection in Africa. The clinical symptoms are manifestations of the massive production of pro-inflammatory cytokines in response to infection and in many outbreaks, mortality exceeds 75%. The unpredictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effective vaccine or therapy have created a high level of public concern about EboV. Here we report the identification of a novel benzylpiperazine adamantane diamide-derived compound that inhibits EboV infection. Using mutant cell lines and informative derivatives of the lead compound, we show that the target of the inhibitor is the endosomal membrane protein Niemann-Pick C1 (NPC1). We find that NPC1 is essential for infection, that it binds to the virus glycoprotein (GP), and that antiviral compounds interfere with GP binding to NPC1. Combined with the results of previous studies of GP structure and function, our findings support a model of EboV infection in which cleavage of the GP1 subunit by endosomal cathepsin proteases removes heavily glycosylated domains to expose the amino-terminal domain, which is a ligand for NPC1 and regulates membrane fusion by the GP2 subunit. Thus, NPC1 is essential for EboV entry and a target for antiviral therapy.
UR - http://www.scopus.com/inward/record.url?scp=80052868218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052868218&partnerID=8YFLogxK
U2 - 10.1038/nature10380
DO - 10.1038/nature10380
M3 - Article
C2 - 21866101
AN - SCOPUS:80052868218
SN - 0028-0836
VL - 477
SP - 344
EP - 348
JO - Nature
JF - Nature
IS - 7364
ER -